| Literature DB >> 28523017 |
Saera Suhail Kidwai1, Ayesha Nageen2, Samina Ghaznavi3, Farhat Bashir4, Jamal Ara5.
Abstract
BACKGROUND ANDEntities:
Keywords: Antibiotic resistance; Culture and sensitivity; Urinary tract infection
Year: 2017 PMID: 28523017 PMCID: PMC5432684 DOI: 10.12669/pjms.332.11569
Source DB: PubMed Journal: Pak J Med Sci ISSN: 1681-715X Impact factor: 1.088
Number (%) of strains of each pathogen sensitive to number of antibiotics.
| Escheraecia. coli | 25 | 37 | 16 | 28 | 2 | 108(58.6%) |
| Klebsiella | 4 | 5 | 1 | 9 | 1 | 20(11%) |
| Staphylococcus. Aureus | 1 | 8 | 5 | 17 | 0 | 31(17%) |
| Pseudomonas | 1 | 3 | 1 | 1 | 0 | 6(3%) |
| Serratia | 1 | 2 | 2 | 2 | 0 | 7(4%) |
| Enterobacter | 1 | 0 | 2 | 5 | 0 | 8(4.3%) |
| Streptococcus | 0 | 0 | 2 | 2 | 0 | 4(2%) |
Percentage of sensitivity of each pathogen to the antibiotics.
| Amikacin | 78 | 70 | 71 |
| Gentamycin | 37 | 50 | 52 |
| Tobramycin | 32 | 21 | 55 |
| Cefuroxime | 25 | 50 | 71 |
| Cefixime | 25 | 40 | 16 |
| Cephradine | 7 | 0 | 47 |
| Cefotaxime | 37 | 47 | 74 |
| Ceftriaxone | 38 | 45 | 58 |
| Ceftazidime | 34 | 45 | 42 |
| Cefoperazone | 25 | 25 | 62 |
| Fosfomycin | 60 | 53 | 65 |
| Imipenem | 93 | 85 | 97 |
| Augmentine | 22 | 45 | 77 |
| Ciprofloxacin | 28 | 40 | 39 |
| Levofloxacin | 28 | 54 | 32 |
| Ofloxacin | 26 | 40 | 32 |
| Moxifloxacin | 27 | 20 | 61 |
| Tazobactam | 69 | 70 | 87 |
| Septran | 16 | 35 | 26 |
| Nitrofurantoin | 59 | 25 | 86 |
Comparative data on antibiotic resistant patterns in local studies over the last five years.
| Lahore-PJMD. 2014. | 402 isolates. E.coli(80%), S.aureus(9%), Proteus(5.4%), Pseudomonas(5.2%). | Penicillin (100%), Cefotaxime(89.7%), Ceftazidime (73.8%), Cephradine (73.8%), Augmentin (62.6%), Gentamycin (59.8%), Cefuroxime (58.2%), Ciprofloxacin (54.2%), Ceftriaxone (43.3%), Imipenem (43.3%) 261 (81%) were declared as Multiple drug resistant.5 (1.5%) were Extensive drug resistant. | Streptomycin (70%), Tazocin (86%), Amikacin (87%) and Norfloxacin (89%) |
| Karachi. Int J Infect Microbiol. 2013. | 100 isolates | E.Coli: Amoxacillin (20%), Cefixime (21%), Cefradine (46.5%), Genta (37%), Ofloxa (28%). Kleb: Amoxacillin (61%), Ceftriaxone (77%), Cefradine (73)%, Genta (77%), ofloxacin (93%). Entero: Amox (16%), Cefixime (21%), Ofloxacin (66%), Cefradine (33%), Gentamicin (100%). | Imipenm (100%) Imipenem (77%) Imipenem (100%) |
| Pak J Zool. 2012 | E.Coli: 310 isolates | Sensitivity: 20%< 5 drugs 14% 5-8 drugs Cipro 57%, ofloxacin 57%, cephradine 60%, septran 87%, norfloxacin62% | Resistance: 65% >8 drugs Imipenem 100%, mero 100%, tazo/pip 97%, amikacin 90%, cef/sulbactam 87%, ceftazi 77%, gentamicin 73% |
| PIMS. 2010 | 100 isolates E.coli. 60%, Pseudo7%, klebsiella13%, S. aureus10%, Enter2% | Amoxacillin (85%), Augmentine (85%), Ciprofloxacin (65%), Levofloxacin (47%), Cefradine (45%), Nitrofurantoin (73%). | Cefoperazone (54%), Ceftriaxone (50%), Amikacin (76%), Imipenem (91%), Pipracillin/Tazobactam (91%), |
| This study: 2016 Karachi | 184 isolates | E.Coli:Cipro 72%, Ofloxacin74%, Levo 72%, Aug 78%, Septran 84%, Cefurox 75%, Ceftriaxone 62%, Cefixime 75%. S.aureus: Cipro 61%, Ofloxacin 68%, Septran74%, Cifixime 84%. Klebsiella:Cipro 60%, Oflox 60%, Cifixime 60%, Aug 55%, Septran 65%, Nitrofurantoin 75%. | E.Coli: Imipenem 93%, Amikacin 78%, Tazo 69%, Fosfomycin 60%, Nitrofurantoin 59%. S.Aureus: Imipenem 97%, Tazo 87%, Nitrofurantoin 86%, Aug 77%, Cefotax 745, Amikacin 71%, Ceftriaxone 58%, Klebsiella:Imipenem 85%, Tazo 70%, Amikacin 70% |